Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

112.23 -1.12 (-0.99%)
Streaming Delayed Price Updated: 11:37 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,640,454
Open 112.89
Bid (Size) 112.23 (3)
Ask (Size) 112.25 (2)
Prev. Close 113.35
Today's Range 112.16 - 113.36
52wk Range 62.07 - 119.96
Shares Outstanding 1,253,809,440
Dividend Yield 2.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Gilead Sciences Gaining or Losing Market Support?
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why.
A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors. 
Via Chartmill

Performance

YTD
+22.15%
+22.15%
1 Month
+16.74%
+16.74%
3 Month
+21.49%
+21.49%
6 Month
+34.96%
+34.96%
1 Year
+47.79%
+47.79%

More News

Read More
Gilead Presents New HIV Treatment And Cure Research Data
Via Benzinga
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
From Gilead Sciences, Inc.
Via Business Wire
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
From Gilead Sciences, Inc.
Via Business Wire
These 3 Dividend Stocks Jumped 15% in a Month—More to Come?
Via MarketBeat
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts
Via Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Gilead Sciences's Options: A Look at What the Big Money is Thinking
Via Benzinga
P/E Ratio Insights for Gilead Sciences
Via Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Via Benzinga
1 Value Stock with Exciting Potential and 2 to Ignore
Via StockStory
Best And Worst Performing S&P 500 Stocks Since Trump's Election Win
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook.
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Gilead Sciences Unusual Options Activity
Via Benzinga
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Via StockStory
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Via MarketBeat
Topics Death
Exposures Death
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
Via Stocktwits
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Via Talk Markets
Topics Stocks / Equities
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.